Will the Addyi female sexual dysfunction pill ever generate any excitement?
Two years after betting $1 billion on the drug, Valeant Pharmaceuticals (VRX) has agreed to sell Sprout Pharmaceuticals, which initially won regulatory approval for the drug, back to its shareholders. The deal ends a lawsuit filed against the drug maker by former Sprout shareholders – and Valeant is providing a $25 million loan.
The move ends a stunning failure by Valeant to successfully market a pill that, while mired in controversy, seemed to mark a turning point in women’s health when it became available in 2015.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect